Pregnancy. Long term treatment may result in numbness, prickling or formication effects in the lower limbs which may, in rare cases, lead to treatment withdrawal.
Indication
Cerebrovascular insufficiency, Functional rehabilitation after cerebrovascular accidents, Auditory, Vestibular and visual disorders of ischaemic aetiology, Stroke
Contra Indication
Concurrent usage with MAOIs.
Dose
N/A
Side Effect
Mild GI disorders, sleep disturbances, palpitations, anxiety, dizziness.
Rarely, wt loss, peripheral neuropathy with abnormal sensations in the lower limbs.
Pregnancy Category
Name :
Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.
Mode of Action
Almitrine and raubasine work together to increase the amount of oxygen brought to the brain and neurosensory tissue, by increasing the oxygen content of arterial blood.
Interaction
Not to be used concurrently with other almitrine-containing preparations.
Potentially Fatal: MAOIs.
Pregnancy Category Note
N/A
Adult Dose
Adult: PO
Auditory, vestibular and visual disorders of ischaemic aetiology; Cerebrovascular insufficiency; Functional rehabilitation after cerebrovascular accidents
Per tab contains almitrine 30 mg and raubasine 10 mg:
1 tab twice daily.
Child Dose
N/A
Renal Dose
N/A
Administration
N/A
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.